CTLA4 and colorectal carcinoma: MSS CRC, however, is insensitive to anti-PD-1 and/or anti-CTLA4 treatment, although MSS CRC has a comparable level of tumor mutational burden as anti-PD-1 responsive cancers (Picard et al, 2020; Yarchoan et al, 2017).